References
- Lankelma J, Lippens R JJ, Drente-Schonk A. Change in transfer rate of methotrexate from spinal fluid to plasma during intrathecal therapy in children and adults. Clin Pharmacokinet 1980; 5: 465
- Lippens R JJ. Methotrexate in the central nervous system prophylaxis of children with acute lymphoblastic leukemia. Nijmegen. 1981, Thesis, Mefar BV Beesterzwaag
- Meadows W T, Gordon J, Massari D J. Declines in IQ, scores and cognitive dysfunctions in children with acute lymphocytic leukemia treated with cranial irradiation. Lancet ii 1981; 1015: 4
- Tamaroff M, Miller D R, Murphy M L. Intermediate and long-term posttherapy neuropsychologic performance in children with acute lymphoblastic leukemia treated without central nervous system radiation. J Pediatr 1982; 101: 524
- Moe P J, Seip M, Finne P H. Intermediate dose methotrexate (IDM) in childhood acute lymphoblastic leukemia in Norway. Acta Paediatr Scand 1981; 70: 73
- Shapiro W R, Young D F, Mehta B M. Methotrexate distribution in cerebrospinal fluid after intravenous ventricular and lumbar injection. N Engl J Med 1975; 293: 161
- Bleyer W A. Intrathecal methotrexate versus central nervous system leukemia. Cancer Drug Deliv 1984; 1: 157
- Lankelma J, Poppe H. Determination of methotrexate in plasma by on-column concentration and ionexchange chromatography. J Chromatogr 1978; 149: 587
- Winograd B J, Lippens R JJ, Oosterbaan M JM. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children. Eur J Clin Pharmacol 1986; 30: 231
- Hryniuk W M, Fisher G A, Bertino J R. S-phase cells of rapidly growing and resting populations. Differences in response to methotrexate. Mol Pharmacol 1969; 5: 557
- Rosenszajn L A, Radnay L. The effect of methotrexate on transformation and mitosis of normal human blood lymphocytes in vitro. Blood 1974; 43: 401
- Lippens R JJ. Methotrexate II. Use in pediatric chemotherapy. Am J Pediatr Hematol Oncol 1984; 6: 397
- Moe P J, Seip M. High dose methotrexate in acute lymphocytic leukemia in childhood. Acta Paediatr Scand 1978; 67: 265
- Wang J J, Al Freeman, Sinks L F. Treatment of acute lymphocytic leukemia by high dose intravenous methotrexate. Cancer Res 1976; 36: 1441
- Al Freeman, Brechner M L, Wang J J. Intermediate dose methotrexate in childhood acute lymphocytic leukemia. Haematol Blood Transfusion 1979; 23: 115
- Sullivan M P, Ramirez I. Curability of Burkitt's lymphoma with high dose cyclophosphamide, high dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol 1985; 3: 627
- Frankel L S, Wang Y M, Shuster J. High dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytoc leukemia: A Pediatric Oncology Group pilot study. J Clin Oncol 1983; 1: 804
- Colls B M, Robson R A, Robinson B A. Serum profiles and safety of intermediate dose (500–1000 mg) methotrexate following i.v. and i.m. administration. Cancer Chemother Pharmacol 1983; 11: 188
- Gilchrist N L, Caldwell J, Watson I D. Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high dose chemotherapy for aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1985; 15: 290
- Lolciec F, Clavel B, Meeus L. Cancer treatment by methotrexate: Rational use following pharmacokinetic study. Int J Nucl Med Biol 1984; 11: 107
- Kimmelberg H K, Kung D, Watson R EE. Direct administration of methotrexate into the central nervous system of primates. Part I. Distribution and degradation of methotrexate in nervous and systemic tissue after intraventricular injection. J Neurosurg 1978; 48: 883